Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $23.489M Beat $17.545M Estimate
Author: Benzinga Newsdesk | August 08, 2024 05:40pm
Nektar Therapeutics (NASDAQ:
NKTR) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. The company reported quarterly sales of $23.489 million which beat the analyst consensus estimate of $17.545 million by 33.88 percent. This is a 14.59 percent increase over sales of $20.499 million the same period last year.
Posted In: NKTR